Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 8/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 0.74 |
| ▸ | AKT2 | P31751 | 4/20 | 0.70 |
| ▸ | GSK3B | P49841 | 3/20 | 0.70 |
| ▸ | KIT | P10721 | 2/20 | 0.70 |
| ▸ | LCK | P06239 | 1/20 | 0.68 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.68 |
| ▸ | JAK2 | O60674 | 1/20 | 0.64 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.59 |
| ▸ | AKT1 | P31749 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3959075 | 1.00 | JAK3 (1.00) | JAK3HTR2CAKT2GSK3BKIT | |
| SCHEMBL1048998 | 1.00 | JAK3 (1.00) | JAK3HTR2CAKT2GSK3BKIT | |
| SCHEMBL1818852 | 0.98 | JAK3 (1.00) | JAK3HTR2CAKT2GSK3BKIT | |
| SCHEMBL31550436 | 0.95 | JAK3 (0.93) | JAK3HTR2CAKT2GSK3BKIT | |
| SCHEMBL2024857 | 0.86 | HTR2C (0.89) | JAK3HTR2CAKT2GSK3BKIT | |
| SCHEMBL2251760 | 0.85 | HTR2C (1.00) | JAK3HTR2CAKT2GSK3BKIT | |
| SCHEMBL10232192 | 0.85 | JAK3 (0.72) | JAK3HTR2CAKT2GSK3BLCK | |
| Piperazine SCHEMBL7852092 | 0.84 | HTR2C (0.97) | JAK3HTR2CAKT2GSK3BKIT | |
| Hydrochloric Acid SCHEMBL2794687 | 0.84 | HTR2C (0.97) | JAK3HTR2CAKT2GSK3BKIT | |
| SCHEMBL31499276 | 0.84 | JAK3 (1.00) | JAK3HTR2CAKT2GSK3BKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160185-A9 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | PALAU PHARMA, S.A. (ES) | 2011-06-30 | — | — | US | disclosed |
| US-20100113420-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | PALAU PHARMA, S.A. (ES) | 2010-05-06 | — | — | US | disclosed |
| US-7569569-B2 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. (US) | 2009-08-04 | — | — | US | disclosed |
| EP-1087971-B1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PROD INC (US) | 2004-07-07 | — | — | EP | disclosed |
| US-20040058922-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2004-03-25 | — | — | US | disclosed |
| US-6635762-B1 | Protein tyrosine kinase or Janus Kinase 3 inhibitors; immunosuppressants | PFIZER INC. | 2003-10-21 | — | — | US | disclosed |
| EP-1087971-A1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065909-A1 | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160185-A9 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | JAK3 1/4885HTR2C 3411/4885AKT2 1555/4885 |
| US-20040058922-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK1, JAK3, JAK2 | JAK3 2/4885HTR2C 3868/4885AKT2 731/4885 |
| US-20100113420-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | JAK3 1/4885HTR2C 3411/4885AKT2 1555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.